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Bowen-Conradi syndrome (BCS) is an autosomal-recessive disorder characterized by severely impaired prenatal and postnatal growth,
profound psychomotor retardation, and death in early childhood. Nearly all reported BCS cases have been among Hutterites, with
an estimated birth prevalence of 1/355. We previously localized the BCS gene to a 1.9 Mbp interval on human chromosome
12p13.3. The 59 genes in this interval were ranked as candidates for BCS, and 35 of these, including all of the best candidates, were
sequenced. We identiﬁed variant NM_006331.6:c.400A/G, p.D86G in the 18S ribosome assembly protein EMG1 as the probable cause
of BCS. This mutation segregated with disease, was not found in 414 non-Hutterite alleles, and altered a highly conserved aspartic acid
(D) residue. A structural model of human EMG1 suggested that the D86 residue formed a salt bridge with arginine 84 that would be dis-
rupted by the glycine (G) substitution. EMG1mRNAwas detected in all human adult and fetal tissues tested. In BCS patient ﬁbroblasts,
EMG1 mRNA levels did not differ from those of normal cells, but EMG1 protein was dramatically reduced in comparison to that of
normal controls. In mammalian cells, overexpression of EMG1 harboring the D86G mutation decreased the level of soluble EMG1
protein, and in yeast two-hybrid analysis, the D86G substitution increased interaction between EMG1 subunits. These ﬁndings sug-
gested that the D-to-G mutation caused aggregation of EMG1, thereby reducing the level of the protein and causing BCS.Introduction
Bowen-Conradi syndrome (BCS [MIM 211180]) is a lethal
autosomal-recessive disorder that was ﬁrst described
in the Hutterite population by Bowen and Conradi.1 As
more patients have been assessed, the characteristic
phenotype has been further delineated.2 It includes
marked prenatal and postnatal growth retardation, micro-
cephaly, a prominent nose with an absent glabellar angle,
micrognathia, joint abnormalities including ﬂexion
contractures, camptodactyly, rocker-bottom feet, and
severe psychomotor delay. Other external abnormalities
are rare, and there are very few internal structural malfor-
mations. Cerebellar anomalies are not evident in magnetic
resonance imaging results, and signs of metaphyseal
dysplasia or other skeletal anomalies have not been identi-
ﬁed in radiologic studies. In addition, no molecular or
metabolic abnormality has been identiﬁed thus far. Most
patients do not survive beyond the ﬁrst year of life, as
a result of complications associated with reduced mobility
and failure to thrive.
To date, virtually all affected babies have been born into
Hutterite families. There are, however, at least four pub-
lished and four unpublished reports of non-Hutterite
babies with BCS-compatible features. These include
a Russian baby,3 a German baby,4 a Turkish baby,5 two
Indian babies,6 and unpublished reports of Pakistani, Bra-
zilian, Ukrainian-Italian, and American (Californian)728 The American Journal of Human Genetics 84, 728–739, June 12babies. In all of these cases, either their clinical photo-
graphs did not convincingly resemble our BCS patients
or inadequate views made it difﬁcult to conﬁrm the diag-
nosis. In addition, structural, central nervous system, and
othermalformations seen in these patients (e.g., macrocor-
nea, sclerocornea, cortical hypoplasia in the brain) have
not been observed in our patients. The features of BCS
also overlap with trisomy 18 syndrome, pseudo-trisomy
18 syndrome, and cerebro-oculo-facial-skeletal syndrome
(COFS). Critical differences do exist, but given the rarity
of BCS in the non-Hutterite population, making a deﬁni-
tive clinical diagnosis can be problematic.
Among Hutterites of the Canadian Prairies, the birth
prevalence of BCS is estimated to be 1/355, predicting
a carrier frequency of 1 in 10 in this population.2 The
Hutterites are one of the Anabaptist sects, which originated
in Southern Tyrol, Austria, in the 16th century. Their
history and social structure have been described previ-
ously.7,8 In brief, after years of religious persecution, they
immigrated to South Dakota in the 1870s and formed
three endogamous subdivisions called leuts (Dariusleut,
Lehrerleut, and Schmiedeleut). They live on farming colo-
nies located predominantly in the Canadian Prairie Prov-
inces and the U.S. Great Plains and constitute a highly
structured population isolate of about 40,000 persons.
The ancestry of themajority of the contemporary Hutterite
population can be traced to fewer than 100 founders.9
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of the general population is most likely due to a founder
effect in this closed population with a small number of
original ancestors.
In a previous study,10 we used 389microsatellite markers
to perform a genome-wide scan on DNA from 42 Hutterite
individuals, representing nine families with at least one
child affected with BCS. Given an assumption that all of
the Hutterite patients are homozygous for the same muta-
tion inherited from a common ancestor, both homozy-
gosity by descent and linkage analyses were employed,
identifying a single region at chromosome band 12p13,
containing the BCS locus. With the use of additional
markers in the 12p13 region and the incorporation of
two additional families with BCS-affected children, the
BCS gene region was narrowed to a 3.5 cM region between
F8VWF andD12S397, for which all of the affected children
are identically homozygous.
Here, we report the identiﬁcation of a NM_006331.6:
c.400A/G, p.D86G defect in the EMG1-encoding gene
(MIM 611531) on chromosome 12p13 as the cause of
BCS in the Hutterite population. The EMG1 protein, also
known as Nep1, has been identiﬁed as essential in yeast
for the biogenesis of 18S ribosomal RNA and the 40S ribo-
some, and the D86 residue is completely conserved in all
EMG1 orthologs that we have analyzed to date. Using
both patient ﬁbroblasts and model systems, we have
demonstrated that the D86G mutation alters the EMG1
protein structure and results in reduced EMG1 protein
levels in the BCS patients.
Subjects and Methods
Study Subjects
The DNA samples used for identiﬁcation of the BCS mutation in
this study were from BCS patients and their relatives and were ob-
tained as part of the previous study mapping the BCS gene.10
Lymphoblast or ﬁbroblast cell lines from patients were generated
as part of that study. Signed informed consent was obtained
from all participants. This study was approved by the Health
Research Ethics Board at the University of Manitoba. Anonymous
control DNA samples were from non-Hutterite Manitobans and
individuals from the eastern United States.
Sequencing
For each gene to be sequenced, the coding sequence was ampliﬁed
by polymerase chain reaction (PCR) with primer pairs at least
30 bp away from each intron-exon junction; exons were ampliﬁed
together if they were separated by a small intron. The sequences of
the oligonucleotide primers used to amplify the exons for each
gene are available on request. PCR was performed in a 50 ml
volume with the use of Taq polymerase (Invitrogen) in accordance
with the manufacturer’s instructions. All PCR reactions started
with a 5 min denaturation step at 95C, followed by 30 cycles of
1 min at 95C, 1 min at the calculated annealing temperature,11
and 2 min at 72C. At the end of the 30 cycles, a 5 min extension
at 72C was performed. When necessary, PCR conditions were
optimized to produce speciﬁc products. The PCR products were
separated by agarose gel electrophoresis, and the DNA fragmentsThe Amwere extracted with a QIAquick Gel Extraction Kit in accordance
with the supplier’s instructions (QIAGEN). DNA sequencing was
performed by The Centre for Applied Genomics, The Hospital
for Sick Children, Toronto, Canada, with the use of the same
primers that were used for PCR ampliﬁcation, unless the fragment
exceeded a size that allowed for accurate sequencing. In such
a case, additional internal primers allowed complete sequencing
of the PCR fragment. The DNA sequence was determined for
both strands of all fragments.
The coding sequence of EMG1 was ampliﬁed as four fragments.
Exon 1 was ampliﬁed as a 370 bp fragment with forward primer
50-CATTTCCTGGCCCACTTTC-30 and reverse primer 50-CCTCTCT
GCTTTCTACATCC-30 (annealing temperature 56C). Exons 2 and
3were ampliﬁed together as a 502bp fragmentwith forward primer
50-GGACCACACTTGAAGAACCAC-30 and reverse primer 50-TTCT
CCCTTTTCCTCTTCCTC-30 (annealing temperature 60C), and
exons 4 and 5 were ampliﬁed together as a 442 bp fragment with
forward primer 50-CCTTGTTCGATGACTGGACAG-30 and reverse
primer 50-GCATTGTTAAAATGCCTACTGC-30 (annealing tempera-
ture 60C). Exon6was ampliﬁed as a 746 bp fragmentwith forward
primer 50-GTTTTCCTGCCCTAAAGAAGG-30 and reverse primer
50-CTCTCCCCATCTAGCCAGG-30 (annealing temperature 60C).
DNA sequencing of these fragments was performed as described
above.
Detection Strategies for APOBEC1
and EMG1 Mutations
The NM_001644.3:c.96G/A, p.W21X mutation in APOBEC1
creates an AvrII site. For detection of themutation, a 295 bp region
of exon 3 was ampliﬁed by PCR with forward primer 50-GGGGAG
CAGGAAAAGATTTC-30 and reverse primer 50-GGACAAGAACCA
GGTGATGG-30 (annealing temperature 59C). A 20 ml aliquot of
the PCR product was digested with 10 U of AvrII at 37C for
1.5 hr. The 206 bp and 89 bp products generated in the presence
of the c.96A/G mutation samples were separated from the
295 bp product on 10% polyacrylamide gels and visualized with
ethidium bromide.
For detection of the c.400A/G, p.D86G mutation in EMG1,
a 104 bp region of exon 2-intron 2 was ampliﬁed with forward
primer 50-GAAGACATATGAGCTACTCAACTG-30 and reverse
primer 50-GAGTTACCTGGTGGGTGGTA-30 (annealing tempera-
ture 56C). The reverse primer contained a single A/G (bolded
in oligonucleotide sequence) substitution that introduced a KpnI
site into the resulting PCR product only in the presence of the
c.400A/G mutation. A 25 ml aliquot of the PCR product was di-
gested with 10 U of KpnI at 37C for 2 hr. The 82 bp and 22 bp
products generated in the presence of the A/G mutation were
separated from the undigested 104 bp PCR product onto an 8%
polyacrylamide gel and visualized as above.
RNA Analyses
Total RNA was isolated from ﬁbroblasts or lymphoblasts with Tri-
zol Reagent in accordance with the instructions of the manufac-
turer (Invitrogen). For examination of gene expression in the
candidate region, 1 mg of total RNA from patient and control
lymphoblasts was reverse transcribed with Omniscript reverse
transcriptase, in accordance with the manufacturer’s instructions
(QIAGEN). For each gene, cDNA was PCR ampliﬁed with two
sets of forward and reverse primers that were speciﬁed to recognize
as many of the transcripts of the gene as possible. The primer
sequences are available upon request.erican Journal of Human Genetics 84, 728–739, June 12, 2009 729
RNA blotting analysis of RNA was performed on 7 mg of total
ﬁbroblast RNA from two BCS-affected patients and one unaffected
control.12 Twenty microliters of RNA samples were mixed with
20 ml of glyoxal loading dye (Ambion) and denatured at 55C for
30 min. The samples were spun brieﬂy in a centrifuge and imme-
diately loaded onto a 1.2% agarose gel made with 13 tris-borate
ethylenediaminetetraacetic acid (EDTA) buffer (TBE buffer). The
samples were then separated by gel electrophoresis at 70 V for
2 hr and 30 min in 13 TBE buffer. The RNA was then transferred
to the Bright Star positive nylon membrane (Ambion) via the
Genie electrophoretic blotter (Idea Scientiﬁc) at 12 V for 90 min
in 13 TBE buffer in accordance with the manufacturer’s instruc-
tions. The agarose gel and the nylon membrane were examined
under UV light, and both 18S and 28S rRNA positions were
marked on the membrane as size markers. The membrane was
then UV cross-linked and prehybridized overnight at 68C with
ExpressHyb solution (BD Biosciences). The glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) and EMG1 cDNA probes
were labeled with 32P (PerkinElmer) to a speciﬁc activity of at least
1 3 109 dpm/mg with the Rediprime II DNA labeling system (GE
Healthcare) and puriﬁed with ProbeQuant G-50 Micro Columns
(GE Healthcare). The membrane was incubated overnight at
68C with 20 ml of fresh ExpressHyb solution containing dena-
tured probe. After hybridization, the membrane was washed
with wash solution 1 (2 3 SSC [300 mM NaCl, 30 mM sodium
citrate], 0.1% sodium dodecyl sulfate [SDS]), followed by wash
solution 2 (0.1 3 SSC [15 mM NaCl, 1.5 mM sodium citrate],
0.1% SDS), then exposed to BioMAX MS (Kodak) ﬁlm for 7 hr at
80C (EMG1) or for 2 hr at room temperature (GAPDH).
The levels of EMG1 mRNA in different human adult and fetal
tissues were determined by semiquantitative PCR with the use of
Human Multiple Tissue cDNA panels I and II (Clontech Laborato-
ries), in accordance with the manufacturer’s instructions. In brief,
5 ng of cDNA from different tissues was ampliﬁed by PCR with
forward primer 50-GGCCAGTCTGGAGACAGTCAAAGGTA-30
and reverse primer 50-CCCATACTTCCTCAAAGGCTGTGGT-30,
for ampliﬁcation of EMG1, and with control primers supplied
with the cDNA panels, for ampliﬁcation of GAPDH. All ampliﬁca-
tions were performed with Titanium Taq DNA Polymerase (Clon-
tech Laboratories) in a 50 ml volume at 95C for 1 min, 22–38
cycles at 95C for 30 s and at 68C for 3 min, followed by ﬁnal
extension at 68C for 3 min. Aliquots were collected at different
cycle numbers, and the ampliﬁed products were separated in





sequences for human (NP_006322.3),mouse (NP_038564.1),Arabi-
dopsis (NP_191259.1), Plasmodium (XP_679765.1), Drosophila
(XP_001355221.1), and Aspergillus (XP_755005.1) orthologs were
selected for multiple alignment. In addition, through the perfor-
mance of a PSI BLAST iteration after the initial BLAST search,
a more distantly related ortholog was identiﬁed in Sulfolobus
(YP_254757.1) and included in the alignment. A multiple align-
ment of these sequences was performed with ClustalW.14
Comparative Molecular Modeling of Human EMG1
A three-dimensional comparative molecular model of human 18S
ribosome assembly protein EMG1 (residues 25–243) was built with730 The American Journal of Human Genetics 84, 728–739, June 12the SWISS-MODEL server,15–17 with the use of the 2.0 A˚ resolution
crystal structure of yeast Emg1monomer (Protein Data Bank [PDB]
code 2v3j) as a template. A model of homodimeric human EMG1
was constructed by superimposing the modeled human EMG1
protein onto the homologous subunits of the 2.2 A˚ resolution
crystal structure of homodimeric ribosome biogenesis protein
NEP1-like from Methanocaldococcus jannaschii (PDB code 3BBE)
with the Dali pairwise comparison server.18 For optimization of
the structural geometry, the modeled human EMG1 homodimer
was placed in a primitive lattice (P1) and subjected to 1000 steps
of conjugate gradient energy minimization, as implemented in
the Crystallography and Nuclear magnetic resonance System
(CNS)version1.21.19Unit cell parameterswere set sufﬁciently large
enough that intermolecular contacts were avoided duringminimi-
zation. The overall quality of the model was assessed with the
WHATCHECK20 and PROCHECK21 routines available from the
SWISS-MODEL server.15–17 Finally, the 2.0 A˚ crystallographic struc-
ture of yeast Emg1 in complex with the methyl donor substrate
S-adenosyl-methionine (SAM) (PDB code 2v3k) was used for
placing SAM molecules into the homologous binding sites of
the modeled human EMG1 homodimer by superimposing
the coordinates of the yeast Emg1:SAM complex onto each of the
monomers of the human EMG1 homodimer with the use of the
Dali pairwise comparison server.18 S-adenosyl-L-homocysteine
(SAH) molecules bound to the ribosome biogenesis protein NEP1-
like ortholog fromM. jannaschii (PDB code 3BBE) were also placed
into the homologous binding sites of modeled human EMG1 ho-
modimer with the use of the Dali pairwise comparison server.18
Vector Construction
Mammalian expression vectors containing the wild-type and
D86G-mutated EMG1 cDNA sequences were constructed via
a PCR-based strategy. In brief, total RNA isolated from normal or
patient ﬁbroblasts was reverse transcribed with Superscript (Invi-
trogen). The coding sequence was ampliﬁed with oligonucleotide
primers that added BamHI and XhoI sites onto the 50 and 30 ends,
respectively. The PCR products were isolated from agarose gels
with the use of a QIAquick kit and digested with BamHI and
XhoI to generate the 755 bp insert. The fragments were ligated
with BamHI- and XhoI-digested pcDNA3.1 (Invitrogen), gener-
ating pcDNAEmg1 and pcDNAEmg1-D86G constructs. For the
generation of constructs that had an HA tag added to the C
terminus of EMG1, these vectors were used as the templates for
PCR ampliﬁcaton with Phusion polymerase (New England Biol-
abs) with forward primer 50-GTGTGGTACCACCATGGCCGCGC
CCAGTGATGGATTC-30 and reverse primer 50-TGTAGCGGCCGC
ATGACCCCCCATACTTCCTCAAAGGC-30 (annealing tempera-
ture 65C). The products were restriction-enzyme digested with
KpnI and NotI and cloned into KpnI- and NotI-digested pMH
plasmid (Roche Applied Science) for the generation of pMH-
EMG1 and pMH-EMG1-D86G plasmids. The full EMG1 coding
region was sequenced for conﬁrmation of the presence of only
the desired A-to-G substitution in the pMH-EMG1-D86G vector.
pRCMVb-gal was purchased from Invitrogen.
Cell Culture, Transfections, and Protein Isolation
Fibroblasts and baby hamster kidney (BHK) cells were maintained
in minimal essential medium (alpha modiﬁcation) containing
10% fetal bovine serum and 100 U penicillin; 100 mg streptomycin
per mL (Invitrogen). Transfections were performed with 4 mg of
plasmid DNA per 30 mm dish with the use of Lipofectamine, 2009
2000 (Invitrogen), per the manufacturer’s speciﬁcations. For isola-
tion of soluble and insoluble fractions, cells were collected into
1.5 ml tubes and lysed in a modiﬁed radio immunoprecipitation
assay (RIPA) buffer (1% tert-Octylphenoxy [poly]oxyethelene
ethanol [IGEPAL]; 0.5% sodium deoxycholate; 0.1% SDS; 1.9 mM
NaH2PO4;8.1mMNa2HPO4;150mMNaCl).RIPA-insolubleprotein
was then separated by centrifugation for 10 min at 10000 3 g, the
supernatant was removed, and the pellet was resuspended in RIPA
buffer and sonicated for 5 s. For isolationof cytoplasmic andnuclear
fractions, cells were ﬁrst lysed in Triton buffer (50 mM Tris pH 7.4;
1 mM EDTA; 150 mM NaCl; 1% Triton) and fractions were then
separated by centrifugation at 20003 g for 10min. The supernatant
was removed, and the pellet was resuspended in nuclear lysis buffer
(50 mM Tris pH 7.4; 10 mM EDTA; 1% SDS) and sonicated. All lysis
buffers were supplemented with protease inhibitors (SIGMA). The
protein concentration was determined with the Bradford (Bio-
Rad) or the bicinchoninic acid (Fisher Scientiﬁc) assay.
Immunoblot Analysis
Aliquots of the cell lysates (20–25 mg of protein) were separated in
a 10% gel by SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred to a nitrocellulose membrane in N-cyclohexyl-
3-aminopropanesulfonic acid (CAPS) buffer pH 11 at 100 V for
1 hr at 4C via a modiﬁed method.22 Proteins were detected with
an EMG1 antibody or a ﬁbrillarin antibody (both from Aviva
SystemsBiology), at a dilutionof1:2000,orwithanHAtag antibody
(Applied Biological Materials), at a dilution of 1:10000, in 5% skim
milk powder in Tris-buffered saline Tween (TBST) (20 mM Tris pH
7.4; 0.15MNaCl; 0.1%Tween). Blots were thenwashed three times
with TBST, incubated with horseradish peroxidase (HRP)-conju-
gated secondary donkey anti-rabbit or donkey anti-mouse antibody
at a dilution of 1:20000, washed, and visualized with Immobilon
western chemiluminescent HRP substrate (Millipore).
Yeast Two-Hybrid Analysis
For fusions of human EMG1with either the Gal4-activation or the
DNA-bindingdomain, theEMG1coding sequencewasampliﬁedby
PCRwith primersC2fBam5 (50-GTCAGGATCCTGGCCGCGCCCA
GTGATGGATTCAAG-30) and C2fPst3 (50-TCAGCTGCAGTCAAAT
GACCCCCCATACTTCCTCAAAGG-30), with a fetal heart cDNA
library used as a template. The PCR products were digested with
BamHI and PstI and inserted into plasmids pGAD424 and pGBT9
(Clontech), resulting in plasmids pGAD424-HsEMG1 and pGBT-
HsEMG1. For the introduction of the D86G mutation (GAT/
GGT) into these constructed plasmids, site-speciﬁc PCR-directed
in vitro mutagenesis was performed with primers C2f-D86G-1 (50-
GGAAGCGCGGCCAGGTATCACCCACCAGA-30) andC2f-D86G-2
(50-TCTGGTGGGTGATACCTGGCCGCGCTTCCC-30), resulting in
plasmids pGAD424-HsEMG1-D86G and pGBT9-HsEMG1-D86G.
The two hybrid plasmids pGAD and pGBT, containing human
EMG1 or EMG1-D86G, were cotransformed into the yeast host
strain PJ69-4A (MATa, trp1-901, leu2-3,112, ura3-52, his3-200,
Dgal4, Dgal80, ade2::GAL2-ADE2, LYS2::GAL1-HIS3, met2::GAL7-
lacZ).23 Reporter gene activation was determined by growth assays
on dropout medium lacking histidine or by measurement of
b-galactosidase activity.
Results
Characterization of Candidate Genes
The candidate interval bounded by F8VWF and D12S397,
based on NCBI Build 36.2, is 1.9 Mbp in size and containsThe Am59 genes that have been demonstrated or predicted to
encode proteins (see Table S1, available online).
The expression of the 59 genes in the candidate interval
was assessed in order to screen for alterations in the level
of a gene transcript(s) that might indicate the presence of
a mutation. Total RNA from patient and normal lympho-
blasts was reverse transcribed and used as a template for
PCR ampliﬁcation of transcripts from each of the genes.
Of the 59 genes, 48 were ampliﬁed from total lympho-
blast-derived cDNA, and the products were the same size
in both normal and BCS lymphoblasts (Table S1). We
were unable to amplify cDNA-representing transcripts
(no transcript; NT) for six of the genes, and ﬁve of the
genes were not analyzed (NA) (Table S1) because they
had not yet been predicted to exist in the region at the
time that the expression analyses were performed.
Although no attempt was made to quantify the expression
of these genes, there were no obvious differences in the
PCR products that would suggest a difference between
BCS and normal lymphoblasts. In the absence of any
obvious differences in the level or size of the PCR products
produced from the transcripts, we moved to sequencing
the genes in the candidate interval.
Sequencing of Candidate Genes
The order of priority for sequencing genes in the candidate
interval was established by ranking the 59 candidate BCS
genes as poor, medium, or good (Table S1) candidates on
the basis of published information about their function
and previous associations with disease, as well as database
information on their expression proﬁle and sequence simi-
larities. In making this assessment, we assumed, because of
the clear neurological deﬁcits in BCS patients, that the
causative gene would normally be expressed in the brain
and would have a vital function. If there was no available
information about the function of the gene, it was auto-
matically ranked as a good BCS candidate. The ranking of
the genes was reassessed on an ongoing basis, allowing
incorporation of new information.
We sequenced all of the 20 genes ranked as good candi-
dates and the 13 genes ranked as medium candidates, as
well as two of the 26 genes ranked as poor candidates. The
coding sequences and the adjacent intron-exon junctions
were sequenced from the DNA of one affected patient,
with the assumption that all patients would be homozy-
gous for the identical mutation. The DNA sequence of
both strands of all PCR products was determined by direct
sequencing, and NT_009759.15 or NT_009714.16 was
used as the reference sequence for comparison. We identi-
ﬁed 59 known and six novel single-nucleotide polymor-
phisms (SNPs) in the course of sequencing (Table S1).
Only those SNPs at the ends of the interval were analyzed,
and they were found to completely segregate with disease
(data not shown); we assumed that the remaining SNPs,
whichwere closer to themiddleof the interval,would segre-
gate with disease as well. The SNPs identiﬁed during
sequencing thus could not be used to reduce the minimalerican Journal of Human Genetics 84, 728–739, June 12, 2009 731
BCS interval. We then assessed the potential for each of
these SNPs to cause BCS.
Of the 59 known SNPs that were identiﬁed, all but six
were located within introns or were synonymous changes.
These six nonsynonymous changes were considered
unlikely to be the cause of BCS, because of their presence
Figure 1. Analysis of the EMG1 Mutation Causing BCS
(A) Sequence chromatograms of a BCS-affected patient (top) and
a normal control (bottom). The position of the A/G mutation is
indicated by an arrow.
(B) Detection of the c.400A/G mutation in a Hutterite family.
The region of EMG1 containing the c.400A/G mutation was ampli-
fied by PCR from the DNA samples of a family with BCS-affected
children with the use of a primer that created a KpnI site only in
the presence of the mutation. The samples were analyzed by
agarose gel electrophoresis. The affected children (black dia-
monds) have only the 82 bp fragment, whereas the parents and
two of the siblings are heterozygous for c.400A/G, as indicated
by the presence of both 104 bp and 82 bp fragments, and one child
is homozygous for normal EMG1, as indicated by the presence of
only the 104 bp fragment.
(C) Protein sequence alignment via Clustal W of the region of the
EMG1 protein containing the c.400A/G, p.D86G mutation. The
residues that are completely conserved in all orthologs are indi-
cated with an asterisk, and the Asp (D) that is mutated in BCS is
shown in red.732 The American Journal of Human Genetics 84, 728–739, June 12in the known SNP database. Also, PLEKHG6 rs740842
(c.251G/A, p.A35T) and DPPA3 rs2024320 (c.229G/C,
p.E51Q) were frequently detected in various populations
and therefore could not be the cause of BCS. In addition,
EMG1 rs17857448 (c.269G/T, p.R42S), and NANOG
rs2889552 (c.256C/A, p.A16E) were located in noncon-
served regions of these proteins and therefore would
be unlikely to cause disease. LEPREL2 rs5705068
(g.6792285_6792286insG) was in the cDNA sequence
NM_014262.3 and the alternate contig assembly
NW_001838050.1 and is probably an error in the reference
contig sequence NT_009759.15. The remaining change,
APOBEC1 rs34275479 (c.96G/A, p.W21X), was consid-
ered a poor candidate to cause disease, because a mouse
knockout of Apobec1 exhibited only a minor change in
lipoprotein levels24 and the mutation was found outside
the Hutterite population and in ﬁve of 414 random alleles
tested in our laboratory, again making it unlikely to be the
cause of BCS.
The six novel SNPs identiﬁed during this study included
ﬁve that were found within the introns. The remaining
SNP, c.400A/G, p.D86G in EMG1 (Figure 1A), destroys
an EcoRV site. However, because this method of detection
is not speciﬁc, we developed an assay in which a KpnI site
was created in the presence of the EMG1 mutation
(Figure 1B). This mutation completely segregated with
disease in the BCS families but was not found in any of
414 alleles examined in DNA samples from non-Hutterites.
To further evaluate the EMG1 variation, we looked at the
conservation of the D86 residue in orthologs to EMG1.
In a multiple alignment of protein sequences derived
from distantly related orthologs, including even Sulfolobus,
a member of Archaea, D86 was found to be completely
conserved. In fact, the D86 residue was found in the
most highly conserved region of the EMG1 protein
(Figure 1C).
Modeling of Human EMG1
A comparative molecular model of the human EMG1
protein was built with the SWISS-MODEL server, initially
with the use of the crystallographic structure of the yeast
Emg1 monomer (PDB code 2v3j) as a template. Human
EMG1 is 52% identical (65% similar) to the yeast Emg1
(also known as Nep1), according to BLAST (BLOSUM62
scoring matrix). The highest degree of sequence conserva-
tion occurs between residues that make up the core a/b
knot fold that is characteristic of SPOUT-class methyltrans-
ferases25 and an additional b-a-b insertion that appears
unique to Emg1 proteins and may be involved in RNA
binding.26,27 This conserved region does not include
the N terminus (approximately 24 amino acids); these
N-terminal residues are poorly conserved between eukary-
otic Emg1 proteins and are absent from their archaeal or-
thologs.26 Thus, only residues 25–243 of human EMG1
were included in the molecular model. Although demon-
strated biochemically, the biological dimer of yeast Emg1
could not be identiﬁed in the crystal structure.26 Thus,, 2009
for the building of a homodimeric model of human EMG1,
the modeled monomers of the protein were superimposed
onto the homologous monomer positions of the crystal
structure of homodimeric ribosome-biogenesis protein
NEP1-like from Methanocaldococcus jannaschii (PDB code
3BBE) via the Dali server. Although human EMG1 and
M. jannaschii Nep1 share only 29% sequence identity
(49% similarity), according to BLAST (BLOSUM62 scoring
matrix), the structural folds of these proteins are highly
conserved, as indicated by the high Dali Z score of 22.1
and a root mean square deviation (RMSD) of ~2.1 A˚ for
181 equivalent a-carbon positions for each monomer.
This high degree of structural similarity allowed for the
construction of a homodimeric model of human EMG1
with very few bad contacts at the dimer interface, even
before energy minimization. Energy minimization easily
relieved all steric clashes between side chains within the
dimer interface, possibly moving these side chains to posi-
tions that would be adopted naturally during dimerization.
The ﬁnal energy-minimized model of dimeric human
EMG1 had good stereochemical properties, according to
WHATCHECK and PROCHECK. With the use of compar-
ison values typical for a 2.0 A˚ crystal structure, a Ramachan-
dran plot of the energy-minimized dimer showed that
95.7% of residues had f, c angles within core and allowed
regions, 2.4% had f, c angles within generously allowed
regions, and only 1.9% (seven residues) had disallowed
f, c angles. Residues with disallowed f, c angles were
found to reside in loop structures on the surface of the




Figure 2. Comparative Molecular Model
of the Human EMG1 Homodimer
(A) Ribbon diagram of the modeled homo-
dimer, with the individual monomers
colored green and blue. Methyl donors
are drawn as sticks.
(B) Close-up view, showing the hydrogen-
bonding interactions of D86 with R84
occurring at the N terminus of a helix 2.
The two parallel a helices from each mono-
mer (a helices 2 and 7) that form the core
of the dimer interface are labeled a2 and
a7 for each monomer.
(C) Electrostatic-potential map of the
solvent-accessible surface of the human
EMG1 homodimer model. The map shows
that the model predicts a positively
charged region (blue) that is homologous
to the RNA-binding groove of Nep1, and
R84 is located in the center of this groove.
Red indicates a negative charge.
ture of yeast Emg1 (residues 56–64
of yeast Emg1). Finally, the binding
of methyl donors into the preformed
binding pocket of Emg1 proteins
was previously found not to induce
conformational changes in the proteins.27 In accordance
with this ﬁnding, the modeled human EMG1 homodimer
(Figure 2A) contained preformed binding pockets for
methyl donors into which SAM and SAH could be ﬁt with-
out altering the conformations of these substrates from
what was determined crystallographically for the yeast
Emg1-SAM26 and Nep1-SAH27 complexes. The human
EMG1 model clearly showed that D86 formed hydrogen
bonds with R84 and therefore stabilized it (Figure 2B).
The model also showed that R84 was present in the posi-
tively charged RNA-binding groove of the EMG1 dimer
(Figure 2C).
EMG1 Expression
The expression of EMG1 in normal adult tissues was ﬁrst
examined by RNA blot analysis. The primary signal was
detected at approximately 1 kb, as expected on the basis
of the size of the mRNA identiﬁed in human. However,
a larger band at approximately 1.7 kb could also be de-
tected on longer exposures (data not shown). Expression
was detected inmost tissues examined, although the stron-
gest signals were in heart, liver, and stomach, followed by
kidney and brain. Given the prominent neurological
involvement in BCS, we had expected strong expression
in the brain. To determine whether the expression might
be greater before birth, we compared the expression of
EMG1 in human adult and fetal tissues, using semiquanti-
tative PCR analysis (Figure 3). EMG1 expression was similar
or higher in most adult tissues, but in the brain, fetal
expression appeared higher than that in the adult.The American Journal of Human Genetics 84, 728–739, June 12, 2009 733
Analysis of the Effects of the EMG1 Mutation
As a ﬁrst step in assessing the effect of the c.400A/G,
p.D86G change, we examined the level of EMG1 expres-
sion by RNA blot, using total RNA prepared from BCS
patient and control ﬁbroblasts. The level of expression
was the same in the patient and control ﬁbroblasts
(Figure 4A), indicating that the mutation did not have
any effect at the RNA level.
To evaluate the effect of the c.400A/G, p.D86G muta-
tion at the protein level, we compared the endogenous
levels of EMG1 in patient and normal ﬁbroblasts. The
nuclear fraction of ﬁbroblast lysates was used for protein
immunoblotting, because EMG1 is concentrated in the
nucleus and was most easily detected by the EMG1 anti-
body in this fraction (data not shown). The level of
EMG1 was found to be dramatically reduced in the BCS-
affected patient as compared to normal ﬁbroblasts,
although the patient ﬁbroblasts did not have a complete
EMG1 deﬁciency (Figure 4B). Fibrillarin, a nucleolar
protein, was used as a loading control.
Determination of the Mechanism
of D86G-Induced Alterations
For further assessment of the consequences of the D86G
substitution at the protein level, constructs encoding
Figure 3. Expression of EMG1 in Adult and Fetal Tissues
Five nanograms of cDNA from various tissues was amplified by PCR
with the use of EMG1- (top panel) or GAPDH-specific primers
(bottom panel). Samples were taken at different cycle numbers,
separated on a 2% agarose gel, and stained with ethidium bromide.
The results for the samples taken at 26 cycles are shown for both
EMG1 and GAPDH. Control cDNA was provided with each panel,
and the PCR reaction was performed in the absence of cDNA for
the blank. Each panel was normalized to the expression levels of
four housekeeping genes: GAPDH, beta-actin, alpha-tubulin, and
phospholipase A2.734 The American Journal of Human Genetics 84, 728–739, June 12HA-tagged forms of wild-type EMG1 or D86G-containing
EMG1, as well as empty vector plasmid as a negative
control, were transiently expressed in BHK cells. In this
cell line, the level of detectable RIPA-soluble EMG1 protein
wasmuch lower when themutation was present, reﬂecting
the endogenous levels in ﬁbroblasts. However, in the
RIPA-insoluble fraction, levels were similar between the
wild-type and D86G-containing EMG1, indicating that
D86G-containing EMG1 preferentially associates with
the insoluble fraction (Figure 5).
Dimerization of EMG1-D86G
The human and the yeast Emg1 proteins strongly inter-
acted with themselves in the yeast two-hybrid system, sug-
gesting that EMG1 functions as a dimer or multimer. With
this same system used for examination of the effect of the
D86G mutation on interaction of EMG1 subunits, a 10-
fold increase in the interaction between the mutant
subunits as compared to the wild-type subunits was de-
tected (Figure 6). The increased interaction afﬁnity was
indeed due to the D86G mutation, because dimers
Figure 4. EMG1 mRNA Expression and Protein Levels in Unaf-
fected Control and Patient Fibroblasts
(A) RNA analysis. Seven micrograms of total RNA isolated from
unaffected control (Ctrl) fibroblasts or BCS-affected patient fibro-
blasts were separated on 1.2% agarose gel and transferred to
a nylon membrane. The membrane was UV cross-linked and probed
with labeled EMG1 (top panel) and GAPDH (bottom panel) cDNA
probes. Film was exposed to the membrane for 7 hr at 80C
(EMG1) or for 2 hr at room temperature (GAPDH). EMG1 is 1068 bp
and GAPDH is 1310 bp; 18S rRNA position is marked.
(B) Immunoblot analysis of EMG1 protein levels. Twenty-five
micrograms of nuclear lysates from unaffected control fibroblasts
and BCS-affected patient fibroblasts were separated on a 10% gel
by SDS-PAGE, and protein was detected by immunoblot with an
EMG1 antibody (top panel). The blot was then stripped and re-
probed for fibrillarin (FBL), a nuclear protein, so that equal loading
was ensured (bottom panel)., 2009
between the EMG1 wild-type subunit and the D86G
mutant subunit had an increased interaction as compared
to the dimer between wild-type subunits (Figure 6).
Discussion
Among Hutterites of the Canadian Prairies, the gene
causing BCS is referred to anecdotally as the Hutterite
gene, probably because of the severity and high frequency
of BCS in this population. This severity, coupled with the
profound neurological impairment in BCS patients,
suggests that the causative gene has a fundamental func-
tion that could affect neurological development. The
carrier frequency for BCS is about 1 in 10 in the Hutterites,
leading to an incidence of about 1 in 355 live births.2
Given the endogamous and isolated nature of the Hutterite
population, we previously postulated that all patients with
BCS were homozygous by descent and, therefore, that BCS
was caused by a single mutation.10 We then reduced the
minimal interval for the disease-causing gene to a 1.9 Mb
region on 12p13.3,10 which was gene-rich and included
numerous genes that were viewed as good candidates to
cause BCS. After sequencing of the candidate genes, 59
known and six novel SNPs were identiﬁed (Table S1). Of
the known SNPs, all caused synonymous changes, were
localized within introns, were detected outside the
Hutterite population, or were found in nonconserved
regions of the protein. The only novel SNP located in
a coding region, c.400A/G in EMG1, segregated
completely with disease, caused a nonsynonymous change
in a highly conserved region of the protein, and was not
found in any of 414 non-Hutterite alleles. Our approach
of assuming homozygosity by descent therefore proved
to be successful, because all of the BCS patients were
homozygous for a 1.9 Mb region, all patients shared the
c.400A/G change in EMG1, and this variant was not
found in any non-Hutterite controls, supporting our orig-
Figure 5. Transient Expression of D86G Mutant and Wild-Type
EMG1 in BHK Cells
The RIPA-soluble fraction from BHK cells transiently expressing
HA-tagged EMG1 was separated from the insoluble fraction by
centrifugation. The insoluble fraction was then resuspended in
RIPA, sonicated before loading of approximately 20 mg of protein,
and separated in a 10% gel by SDS-PAGE. Protein was then trans-
ferred to a nitrocellulose membrane and detected by immunoblot
with an HA antibody. Cells were cotransfected with pRCMVb-gal
to serve as a transfection control; loading was therefore corrected
for both protein concentration and b-galactosidase activity.
Abbreviations are as follows: V, vector control; WT, wild-type
protein; M, mutant D86G protein.The Aminal hypothesis. The identiﬁcation of a defect in the
EMG1 gene that is essential for growth and mitosis in
yeast28 was also consistent with our expectation that the
gene responsible for BCS would have a fundamental
function.
Very little is known about EMG1 in humans, because the
function of the EMG1 protein has been investigated only
in yeast. The gene is essential in yeast, and through study
of the effects of Emg1 deﬁciency, it has been shown that
these yeast have reduced production of 18S rRNA and
40S ribosomes.28,29 Yeast Emg1 is a component of the
small subunit (SSU) processome30 and plays an essential
role in the biogenesis of the ribosomal 40S subunit. In
particular, it aids in the maturation of 18S rRNA, where it
is thought to participate in a methylation event, using
SAM as a methyl donor.28,29,31 In eukaryotes, synthesis
and assembly of the ribosomal subunits is a complicated
process involving hundreds of factors. The precursor
35S rRNA must undergo many modiﬁcations during
maturation into 5.8S, 25S, and 18S rRNA.32 Bioinformatic
analysis has identiﬁed EMG1 as a member of the SPOUT
superfamily of methyltransferases, of which all of the char-
acterized members bind and modify tRNA or rRNA by
methylation of the ribose 20-OH group, guanine N1, or
uridine N3.25 It has also been shown to play a role in the
removal of snR57, the snoRNA component of the snoRNP
responsible for the 20-OH ribose methylation of G1570 in
18S rRNA, as well as the recruitment of ribosomal protein
RPS19 to the maturing ribosome.31 Ribosomal biogenesis
and the cell cycle are tightly linked, with a checkpoint at
the G1/S boundary ensuring sufﬁcient ribosome levels
before cell division.33,34 Notably, depletion of SSU proces-
some components in yeast is known to cause cell-cycle
arrest in G1.35 In the absence of EMG1, the cell may there-
fore be unable to produce sufﬁcient 40S ribosomal
subunits to sustain normal proliferation.
In order to better understand the possible effects of
a D86G substitution on the structure and function of the
protein, we built a model of human EMG1 based on the
yeastmonomer and the archaebacterial dimer crystal struc-
tures. Bioinformatic analysis of the Saccharomyces cerevisiae
ortholog of EMG1 identiﬁed the yeast equivalent of D86 as
a ‘‘potentially functionally important’’ residue.25 Crystal-
structure examination of theMethanocaldococcus jannaschii
ortholog of EMG1 has also suggested a role for the archae-
bacterial equivalent of D86. D86 strongly hydrogen bonds
arginine (R) 84, another conserved residue, and orients it,
allowing it to bind to RNA.27 It has also been shown that
mutating the yeast equivalent of R84 severely reduces
RNA binding,26,27 providing further evidence of an essen-
tial role for D86 in the binding and subsequent modiﬁca-
tion of the 18S rRNA.
In solution, EMG1 is present as a homodimer26,27 and
D86 is positioned near the interface between the two
subunits. Two parallel a helices (a2 and a7) form the core
of the dimer interface (Figure 2A). D86 is located at the N
terminus of a7 and accepts two hydrogen-bondingerican Journal of Human Genetics 84, 728–739, June 12, 2009 735
Figure 6. Yeast Two-Hybrid Analysis
of Dimerization of EMG1-D86G
Interactions between wild-type EMG1 and
the D86G mutant monomers, as well as
each monomer with itself, were analyzed
in the yeast two-hybrid system. Wild-type
and mutant EMG1 were fused to the Gal4-
activation or DNA-binding domain and
tested against each other by coexpression
in the two-hybrid yeast strain PJ69-4A.
For quantification of binding affinity,
b-galactosidase activity was measured.
Data are from two independent yeast clones
and the error bars represent standard devia-
tion. A two-tailed, independent t test
between Ad-EMG1þBdEMG1 and Ad-EMG1-
D86GþBd-EMG1-D86G showed that b-gal
transcriptional activity in the mutant dimer
was significantly higher with p ¼ 0.0012.interactions from R84, rigidly holding this latter residue in
position (Figure 2B). Our model suggests multiple reasons
that D86G causes functional disruption of human EMG1.
First, the R84 ortholog in Nep1 (R54) has been implicated
in the RNA-binding activity of this protein.27 The residue is
centrally located in a positively charged groove on the
Nep1 homodimer, and our model predicted this RNA-
binding groove to be present in the human EMG1 homo-
dimer (Figure 2C). Thus, the D86G substitution could
disrupt the otherwise rigidly held conformation of R84
and reduce its contribution to RNA binding, a hypothesis
that is supported by the ﬁnding that an alanine mutation
of R88 in yeast Nep1 (R84 in human EMG1) abolishes the
ability of Nep1 to bind RNA.27 Second, introduction of
a glycine at position 86 of human EMG1may result in local
misfolding of the N terminus of the a7 helix. The high
conformational ﬂexibility that would result from the intro-
duction of a glycine in this position could mitigate the
stabilizing effect of proline (P) 85, a residue type that has
a rigidly constrained f angle and is often found at the
beginning of a helices. Although D86 does not appear
to participate directly in the dimer interface, local misfold-
ing on the N terminus of the a7 helix could deform the
dimerization interface and possibly expose core hydro-
phobic residues, thereby reducing the ability of the protein
to dimerize correctly. This may explain the observed aber-
rant dimerization in the D86G protein (Figure 6). Incorrect
dimerization would also affect the formation of the RNA-
binding groove and could potentially reduce protein solu-
bility and stability. This latter hypothesis is supported by
our ﬁnding that human EMG1 containing the D86G
substitution preferentially associated with a RIPA-insoluble
fraction when overexpressed in BHK cells (Figure 5). Taken
together, these results suggest that D86 is responsible for
stabilizing R84, a residue that appears to be important for
RNA binding and may be involved in maintaining proper
secondary structure that is required for correct dimeriza-
tion and protein stability.736 The American Journal of Human Genetics 84, 728–739, June 12,The human EMG1 model clearly demonstrated a critical
role for D86 in maintaining the structure and the function
of the protein. Therefore, we examined patient and control
ﬁbroblasts to assess whether the defect had an effect on
either EMG1 expression or EMG1 protein levels. RNA
blot analysis of total ﬁbroblast RNA did not show any
difference in EMG1 expression between patients and
a control. However, immunoblots created of nuclear
extracts from ﬁbroblasts with the use of an EMG1 antibody
showed that endogenous EMG1 levels were substantially
reduced in BCS patients as compared to those of controls
(Figure 4). EMG1 was not detected in the cytoplasmic frac-
tion (data not shown). Thus, the defect caused by the
c.400A/G mutation was present not at the RNA level,
but at the protein level. Overexpression of HA-tagged
EMG1 in BHK cells showed that the D86G protein was
preferentially associating with an insoluble fraction
(Figure 5). These results may indicate that the D86G
EMG1 aggregated, leading to its degradation. In the over-
expressing model, it is possible that the rate of overexpres-
sion was so high that it overwhelmed the proteasome and
therefore allowed us to see the accumulation in the RIPA-
insoluble fraction. In the ﬁbroblasts, endogenous EMG1
was expressed at much lower levels, and although D86G
EMG1 may have aggregated, the cell was able to degrade
it more quickly and the accumulation seen in the BHK cells
was not apparent. It is important to note that the D86G
substitution causes a partial deﬁciency of EMG1 in BCS
patients. Immunoblots of patient ﬁbroblasts showed that
although EMG1 was reduced in comparison to normal
controls, protein was still present in the nuclear fraction
(Figure 4B). This remaining protein is presumably func-
tional, because a complete deﬁciency would probably be
lethal much earlier on, as indicated by the necessity for
Emg1 in yeast. It is possible that the presence of some
functional EMG1 in BCS patients allows the assembly
of enough ribosomes to promote cell division and prolifer-
ation during fetal development but limits neurological2009
development, leading to the CNS symptoms seen in BCS
patients.
The notion that EMG1 might play a role in fetal brain
development is supported by its expression pattern. PCR
with EMG1-speciﬁc primers on a semiquantitative
multiple-tissue cDNA panel showed that the gene is ubiq-
uitously expressed. However, it appeared to be decreased in
the adult brain in comparison to the fetal brain (Figure 3),
which may indicate a role for EMG1 in neurological devel-
opment. This feature of a broadly expressed gene having
a cell-type-speciﬁc phenotype is not unique among ribo-
somal proteins. Mutations in the mouse Rps19 and Rps20
ribosomal ssu proteins, which play a role in pigmentation,
cause different phenotypic outcomes depending on cell
type. The mutations also have opposite effects during
embryogenesis and postnatal development.36 Further
investigation is for the determination of EMG1’s role in
speciﬁc cell types and at different stages of development.
The association of defects in ribosomal RNA synthesis
with human disease is not new, although there is at present
no single unifying factor linking them clinically. The ribo-
somal biogenesis diseases vary in phenotype, mode of
inheritance, and severity. Patients with Diamond-Blackfan
anemia (DBA [MIM 105650]), Shwachman-Diamond
syndrome (SDS [MIM 260400]), dyskeratosis congenita
(DC [MIM 305000]), and cartilage-hair hypoplasia (CHH
[MIM 250250]), all of which are caused by defects in genes
related to ribosome biogenesis, display bone marrow
failure (reviewed in 37). This feature has not been observed
in Treacher Collins syndrome (TCS [MIM 154500]),
a disease implicating rDNA transcription,38 or in BCS.
Mode of inheritance varies as well: for example, TCS is
autosomal dominant, whereas DC is X-linked recessive,
in contrast with BCS, which is autosomal recessive. It is
interesting to note that 25% of patients with DBA carry
mutations in the gene encoding RPS19,39 the ribosomal
protein also implicated in the function of EMG1.31
Although the two diseases do share some features, such
as craniofacial abnormalities and mental retardation,
DBA is extremely variable, the same mutation frequently
being associated with varying degrees of severity of the
disease.40 It will be interesting to more closely compare
the phenotype and natural history of BCS with other disor-
ders resulting from defects in ribosome biogenesis, but this
has not been done to date, because the babies with BCS
largely have succumbed at a very early age or have been
cared for at home and thus have not been systematically
available for long-term followup.
Our ﬁnding that D86G EMG1 causes BCS will have an
immediate impact on the Hutterite population, because
accurate carrier testing and prenatal diagnosis for individ-
uals at risk can now be offered. Whether BCS exists outside
the Hutterite population is yet to be determined. We have
analyzed the coding sequence of EMG1 in four non-
Hutterite patients that had some similarities to patients
with BCS, but no mutations were found. In the case indi-
viduals for whom enough material was available and theThe Amparents were known to be consanguineous, we were also
able to demonstrate that they were not homozygous
in the 12p13 region, suggesting that these cases have
a different molecular basis (data not shown). Nonetheless,
it is possible that other disease-causing mutations exist
within EMG1, resulting in similar phenotypes. Disorders
such as pseudo-trisomy 18 mimic BCS, both within the
Hutterite population and in other communities, and
EMG1 gene testing will assist in the workup of patients
with this phenotype. In the long term, EMG1 studies will
help us to better understand the pathogenesis of BCS and
other ribosomal biogenesis diseases. The ﬁnding that
EMG1 is only partially deﬁcient in BCS patients is encour-
aging for the possibility of a future treatment for the
disease.
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